Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

Phase 2

Completed

Conditions: Leukemia
Myelodysplastic Syndrome
Lymphoma

Interventions: Device: CliniMACS Fractionation system (Arm A)
Device: CliniMACS Fractionation system (Arm B)
Biological: Haploidentical donor CD34+ cells

First Posted Date: 2012-09-10

Last Posted Date: 2022-08-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 84

Registration Number: NCT01682226

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Dabrafenib

First Posted Date: 2012-09-10

Last Posted Date: 2020-05-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT01682213

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care

Completed

Conditions: Minority Smokers

Interventions: Behavioral: Patient Navigator

First Posted Date: 2012-09-03

Last Posted Date: 2021-07-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT01678118

Locations: 🇺🇸
Ralph Lauren Center for Cancer Care and Prevention, New York, New York, United States
🇺🇸
Heritage Health Center, New York, New York, United States

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Phase 2

Terminated

Conditions: Myeloproliferative Neoplasms

Interventions: Drug: AUY922

First Posted Date: 2012-08-17

Last Posted Date: 2016-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT01668173

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy

Completed

Conditions: Metastatic Cancer or Locally Advanced
Patients Receiving Palliative Radiation

Interventions: Behavioral: questionnaires

First Posted Date: 2012-08-17

Last Posted Date: 2015-07-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT01667965

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness

Active, not recruiting

Conditions: Pediatric or Young Adult Cancer Survivors

Interventions: Genetic: Family History Questionnaire (FHQ)
Genetic: Salvia sample
Other: Blood sample

First Posted Date: 2012-08-17

Last Posted Date: 2024-11-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1068

Registration Number: NCT01667952

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

Completed

Conditions: Head and Neck Cancers

Interventions: Radiation: Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I

First Posted Date: 2012-08-14

Last Posted Date: 2018-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT01664936

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Drug: 3F8 Monoclonal Antibody Combined with Interleukin-2

First Posted Date: 2012-08-10

Last Posted Date: 2021-05-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT01662804

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk

Completed

Conditions: Cancer Free Women

Interventions: Behavioral: questionnaire

First Posted Date: 2012-07-25

Last Posted Date: 2023-01-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 437

Registration Number: NCT01649661

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Cytomegalovirus

Interventions: Biological: CMV-pp65 CTLs

First Posted Date: 2012-07-20

Last Posted Date: 2020-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT01646645

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy